Invitrogen™ Ebdarokimab Recombinant Monoclonal Antibody

Ebdarokimab, also known as AK101, is a monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), two cytokines implicated in the inflammatory response associated with plaque psoriasis. Interleukin-12 subunit beta (IL-12b), also known as IL-12p40, is a crucial component of the heterodimeric cytokine IL-12 and IL-23. The IL-12b gene is located on chromosome 5q31-33 and encodes for a 40 kDa protein. IL-12 is composed of two subunits, p35 and p40, while IL-23 is composed of p19 and the shared p40 subunit. The IL-12b protein has a four-helix bundle structure, homologous to other members of the hematopoietin superfamily. Functionally, IL-12b plays a significant role in immune responses by promoting the differentiation of naive T cells into Th1 cells and enhancing the cytotoxic activity of natural killer (NK) cells. It is essential in the immune system's response to intracellular pathogens. Dysregulation of IL-12b has been implicated in various autoimmune diseases and cancers, making it a target for therapeutic interventions.